{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:35:14Z","timestamp":1793068514244,"version":"4.5.0"},"reference-count":159,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Zeitschrift f\u00fcr Medizinische Physik"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.zemedi.2026.03.011","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T23:36:04Z","timestamp":1774136164000},"page":"268-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5451-4717","authenticated-orcid":false,"given":"Sandra","family":"Resch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Delker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.zemedi.2026.03.011_b0005","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.zemedi.2026.03.011_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejro.2023.100477","article-title":"Current and upcoming radionuclide therapies in the direction of precision oncology: a narrative review","volume":"10","author":"Shah","year":"2023","journal-title":"Eur J Radiol Open"},{"issue":"6","key":"10.1016\/j.zemedi.2026.03.011_b0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061367","article-title":"PSMA theranostics: review of the current status of PSMA-Targeted imaging and radioligand therapy","volume":"12","author":"Jones","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.zemedi.2026.03.011_b0020","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15061733","article-title":"Clinical advances and perspectives in targeted radionuclide therapy","volume":"15","author":"Lepareur","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.zemedi.2026.03.011_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1187870","article-title":"Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade","volume":"14","author":"Al-Toubah","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"10.1016\/j.zemedi.2026.03.011_b0030","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00259-023-06226-z","article-title":"EANM enabling guide: how to improve the accessibility of clinical dosimetry","volume":"50","author":"Gear","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"10.1016\/j.zemedi.2026.03.011_b0035","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1007\/s00259-018-4044-x","article-title":"Correlation of dose with toxicity and tumour response to (90)Y- and (177)Lu-PRRT provides the basis for optimization through individualized treatment planning","volume":"45","author":"Cremonesi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2967\/jnumed.123.265986","article-title":"Long-term nephrotoxicity of (177)Lu-PSMA radioligand therapy","volume":"65","author":"Steinhelfer","year":"2024","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0045","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.zemedi.2026.03.011_b0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.114.148437","article-title":"Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"56","author":"Ilan","year":"2015","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.zemedi.2026.03.011_b0055","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.2967\/jnumed.123.266991","article-title":"Relationship between absorbed dose and response in neuroendocrine tumors treated with [(177)Lu]Lu-DOTATATE","volume":"65","author":"Warfvinge","year":"2024","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.zemedi.2026.03.011_b0060","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2967\/jnumed.123.267023","article-title":"Absorbed dose-response relationship in patients with gastroenteropancreatic neuroendocrine tumors treated with [(177)Lu]Lu-DOTATATE: one step closer to personalized medicine","volume":"65","author":"Hebert","year":"2024","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1016\/j.zemedi.2026.03.011_b0065","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.2967\/jnumed.122.264953","article-title":"Prediction of response to (177)Lu-PSMA therapy based on tumor-to-kidney ratio on pretherapeutic PSMA PET\/CT and Posttherapeutic tumor-dose evaluation in mCRPC","volume":"64","author":"Hohberg","year":"2023","journal-title":"J Nucl Med"},{"issue":"4 Suppl","key":"10.1016\/j.zemedi.2026.03.011_b0070","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/cncr.24796","article-title":"177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy","volume":"116","author":"Garkavij","year":"2010","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.zemedi.2026.03.011_b0075","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2967\/jnumed.123.266843","article-title":"SPECT\/CT image-derived absorbed dose to red marrow correlates with hematologic toxicity in patients treated with [(177)Lu]Lu-DOTATATE","volume":"65","author":"Blakkisrud","year":"2024","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.zemedi.2026.03.011_b0080","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2967\/jnumed.118.225235","article-title":"Bone marrow absorbed doses and correlations with hematologic response during (177)Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases","volume":"60","author":"Hagmarker","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0085","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40658-016-0157-0","article-title":"A novel planar image-based method for bone marrow dosimetry in (177)Lu-DOTATATE treatment correlates with haematological toxicity","volume":"3","author":"Svensson","year":"2016","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.zemedi.2026.03.011_b0090","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.125.270170","article-title":"Lesion absorbed dose-response relationship in patients with metastatic castration-resistant prostate cancer undergoing [(177)Lu]Lu-PSMA-617 radiopharmaceutical therapy","author":"Grkovski","year":"2025","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.zemedi.2026.03.011_b0095","article-title":"Correlation of an index-lesion-based SPECT dosimetry method with mean tumor dose and clinical outcome after (177)Lu-PSMA-617 radioligand therapy","volume":"11","author":"V\u00f6lter","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"10.1016\/j.zemedi.2026.03.011_b0100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2967\/jnumed.118.219352","article-title":"Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes","volume":"60","author":"Violet","year":"2019","journal-title":"J Nucl Med"},{"issue":"14","key":"10.1016\/j.zemedi.2026.03.011_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17142313","article-title":"Feasibility of automated image-based red bone marrow dosimetry for [(177)Lu]Lu-PSMA radiopharmaceutical therapy of metastatic castration-resistant prostate cancer","volume":"17","author":"Rumiantcev","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.zemedi.2026.03.011_b0110","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13277-011-0286-y","article-title":"An overview of targeted alpha therapy","volume":"33","author":"Kim","year":"2012","journal-title":"Tumour Biol"},{"issue":"7","key":"10.1016\/j.zemedi.2026.03.011_b0115","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s00259-024-07017-w","article-title":"First-in-human SPECT\/CT imaging of [(211)At]PSMA-5: targeted alpha therapy in a patient with refractory prostate cancer","volume":"52","author":"Watabe","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5_suppl","key":"10.1016\/j.zemedi.2026.03.011_b0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS275","article-title":"Phase Ib\/IIa dose escalation and expansion study of [212Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb-phase I\/II study","volume":"43","author":"Hansen","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.zemedi.2026.03.011_b0125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/ph8020321","article-title":"A critical review of alpha radionuclide therapy-how to deal with recoiling daughters?","volume":"8","author":"de Kruijff","year":"2015","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.zemedi.2026.03.011_b0130","unstructured":"ITM and CNL Announce the launch of actineer, a new joint venture in the global production of actinium-225. 2023."},{"issue":"9","key":"10.1016\/j.zemedi.2026.03.011_b0135","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1097\/MNM.0000000000001594","article-title":"Challenges and opportunities in developing Actinium-225 radiopharmaceuticals","volume":"43","author":"Dhiman","year":"2022","journal-title":"Nucl Med Commun"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0140","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s41181-025-00362-7","article-title":"(212)Pb in targeted radionuclide therapy: a review","volume":"10","author":"Scaffidi-Muta","year":"2025","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0145","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40658-022-00469-9","article-title":"Protection from contamination by (211)At, an enigmatic but promising alpha-particle-emitting radionuclide","volume":"9","author":"Ohnuki","year":"2022","journal-title":"EJNMMI Phys"},{"issue":"Suppl 1","key":"10.1016\/j.zemedi.2026.03.011_b0150","first-page":"83s","article-title":"Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate","volume":"46","author":"Valkema","year":"2005","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.zemedi.2026.03.011_b0155","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2967\/jnumed.122.264944","article-title":"PSMA-GCK01: A generator-based (99m)Tc\/(188)Re theranostic ligand for the prostate-specific membrane antigen","volume":"64","author":"Cardinale","year":"2023","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.zemedi.2026.03.011_b0160","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13139-014-0315-z","article-title":"Production of (177)Lu for targeted radionuclide therapy: available options","volume":"49","author":"Dash","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"issue":"28","key":"10.1016\/j.zemedi.2026.03.011_b0165","doi-asserted-by":"crossref","first-page":"19926","DOI":"10.1039\/D4RA02694B","article-title":"Separation of terbium as a first step towards high purity terbium-161 for medical applications","volume":"14","author":"Arman","year":"2024","journal-title":"RSC Adv"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0170","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40658-020-00301-2","article-title":"Radiation doses from (161)Tb and (177)Lu in single tumour cells and micrometastases","volume":"7","author":"Alcocer-\u00c1vila","year":"2020","journal-title":"EJNMMI Phys"},{"issue":"16_suppl","key":"10.1016\/j.zemedi.2026.03.011_b0175","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1200\/JCO.2025.43.16_suppl.5010","article-title":"First-in-human results of terbium-161[161Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase I\/II study","volume":"43","author":"Buteau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.zemedi.2026.03.011_b0180","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2967\/jnumed.112.107540","article-title":"A unique matched quadruplet of terbium radioisotopes for PET and SPECT and for \u03b1- and \u03b2- radionuclide therapy: an in vivo proof-of-concept study with a new receptor-targeted folate derivative","volume":"53","author":"M\u00fcller","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.zemedi.2026.03.011_b0185","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3389\/fmed.2019.00132","article-title":"Rhenium-188 labeled radiopharmaceuticals: current clinical applications in oncology and promising perspectives","volume":"6","author":"Lepareur","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.zemedi.2026.03.011_b0190","unstructured":"estar - stopping-power and range tables for electrons. NIST National Institute Standards and Technology."},{"key":"10.1016\/j.zemedi.2026.03.011_b0195","unstructured":"MIRDSoft - MIRDSPECS. Terbium-161 24.09.2025]; Available from: https:\/\/mirdsoft.org\/resources\/mirdspecs."},{"issue":"10","key":"10.1016\/j.zemedi.2026.03.011_b0200","doi-asserted-by":"crossref","DOI":"10.3390\/ph15101292","article-title":"[(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.zemedi.2026.03.011_b0205","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.2967\/jnumed.120.258889","article-title":"First-in-humans study of the SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety, and efficacy","volume":"62","author":"Baum","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.zemedi.2026.03.011_b0210","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2967\/jnumed.122.264857","article-title":"A single-arm, low-dose, prospective study of 177Lu-EB-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"64","author":"Wang","year":"2023","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.zemedi.2026.03.011_b0215","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1055\/s-0040-1720954","article-title":"Yttrium-90 radioembolization dosimetry: what trainees need to know","volume":"37","author":"Villalobos","year":"2020","journal-title":"Semin Intervent Radiol"},{"issue":"5","key":"10.1016\/j.zemedi.2026.03.011_b0220","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2967\/jnumed.124.267611","article-title":"Is (161)Tb really happening?","volume":"65","author":"Kong","year":"2024","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.zemedi.2026.03.011_b0225","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","article-title":"First-in-human results of terbium-161 [(161)Tb]Tb-PSMA-I&T dual beta-Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1\/2 study","volume":"26","author":"Buteau","year":"2025","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.zemedi.2026.03.011_b0230","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","article-title":"An overview of targeted alpha therapy with (225)Actinium and (213)Bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr Radiopharm"},{"issue":"5","key":"10.1016\/j.zemedi.2026.03.011_b0235","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","article-title":"Efficacy and safety of (225)Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study","volume":"49","author":"Yadav","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0240","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00259-021-05474-1","article-title":"Dosing (225)Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity","volume":"49","author":"Kratochwil","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.zemedi.2026.03.011_b0245","article-title":"Efficacy and safety of (225)Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis","volume":"12","author":"Ma","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0250","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12885-024-11900-y","article-title":"Evaluation of the tolerability and safety of [(225)Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study","volume":"24","author":"Ling","year":"2024","journal-title":"BMC Cancer"},{"issue":"9","key":"10.1016\/j.zemedi.2026.03.011_b0255","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted alpha-emitter therapy with (212)Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-humans dose-escalation clinical trial","volume":"63","author":"Delpassand","year":"2022","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.zemedi.2026.03.011_b0260","doi-asserted-by":"crossref","first-page":"732","DOI":"10.2967\/jnumed.124.269299","article-title":"First-in-human phase 0 study of AB001, a prostate-specific membrane antigen-targeted (212)Pb radioligand, in patients with metastatic castration-resistant prostate cancer","volume":"66","author":"Berner","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.zemedi.2026.03.011_b0265","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.109.062604","article-title":"Intraperitoneal \u03b1-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab\u2032)2\u2014a phase I study","volume":"50","author":"Andersson","year":"2009","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0270","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41181-016-0008-2","article-title":"Alpha-PET with terbium-149: evidence and perspectives for radiotheragnostics","volume":"1","author":"M\u00fcller","year":"2017","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"8","key":"10.1016\/j.zemedi.2026.03.011_b0275","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2967\/jnumed.111.100123","article-title":"MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy","volume":"53","author":"Dewaraja","year":"2012","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0280","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40658-021-00385-4","article-title":"Comparison of different methods for post-therapeutic dosimetry in [(177)Lu]Lu-PSMA-617 radioligand therapy","volume":"8","author":"Rosar","year":"2021","journal-title":"EJNMMI Phys"},{"issue":"21","key":"10.1016\/j.zemedi.2026.03.011_b0285","doi-asserted-by":"crossref","first-page":"8329","DOI":"10.1088\/0031-9155\/60\/21\/8329","article-title":"Uncertainty propagation for SPECT\/CT-based renal dosimetry in (177)Lu peptide receptor radionuclide therapy","volume":"60","author":"Gustafsson","year":"2015","journal-title":"Phys Med Biol"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0290","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0969-8043(98)00023-2","article-title":"Radiation dosimetry in nuclear medicine","volume":"50","author":"Stabin","year":"1999","journal-title":"Appl Radiat Isot"},{"issue":"3","key":"10.1016\/j.zemedi.2026.03.011_b0295","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry\u2013standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.zemedi.2026.03.011_b0300","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1088\/0031-9155\/41\/10\/001","article-title":"Dose-rate effects in targeted radiotherapy","volume":"41","author":"Dale","year":"1996","journal-title":"Phys Med Biol"},{"issue":"2","key":"10.1016\/j.zemedi.2026.03.011_b0305","first-page":"37s","article-title":"MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates","volume":"40","author":"Siegel","year":"1999","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.zemedi.2026.03.011_b0310","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s11307-015-0839-3","article-title":"The influence of early measurements onto the estimated kidney dose in [(177)Lu][DOTA(0),Tyr(3)]octreotate peptide receptor radiotherapy of neuroendocrine tumors","volume":"17","author":"Delker","year":"2015","journal-title":"Mol Imaging Biol"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0315","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2967\/jnumed.117.196261","article-title":"Radar dose estimate report: a compendium of radiopharmaceutical dose estimates based on OLINDA\/EXM Version 2.0","volume":"59","author":"Stabin","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.zemedi.2026.03.011_b0320","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.2967\/jnumed.119.240366","article-title":"OpenDose: open-access resource for nuclear medicine dosimetry","volume":"61","author":"Chauvin","year":"2020","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0325","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40658-021-00369-4","article-title":"Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T","volume":"8","author":"Brosch-Lenz","year":"2021","journal-title":"EJNMMI Phys"},{"issue":"2","key":"10.1016\/j.zemedi.2026.03.011_b0330","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1088\/0031-9155\/57\/2\/517","article-title":"A free database of radionuclide voxel S values for the dosimetry of nonuniform activity distributions","volume":"57","author":"Lanconelli","year":"2012","journal-title":"Phys Med Biol"},{"key":"10.1016\/j.zemedi.2026.03.011_b0335","unstructured":"GATE. Available from: http:\/\/www.opengatecollaboration.org\/."},{"key":"10.1016\/j.zemedi.2026.03.011_b0340","unstructured":"FLUKA. Available from: https:\/\/www.fluka.eu\/Fluka\/www\/html\/fluka.php?"},{"issue":"6","key":"10.1016\/j.zemedi.2026.03.011_b0345","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3109\/0284186X.2011.584559","article-title":"The accuracy of absorbed dose estimates in tumours determined by quantitative SPECT: a Monte Carlo study","volume":"50","author":"Ljungberg","year":"2011","journal-title":"Acta Oncol"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0350","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13550-019-0548-z","article-title":"3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT\/CT","volume":"9","author":"Gosewisch","year":"2019","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.zemedi.2026.03.011_b0355","unstructured":"Mustafovic S, Thielemans K. Additive and multiplicative versions of the maximum a posteriori algorithm with median root prior. in 2001 IEEE Nuclear Science Symposium Conference Record (Cat. No.01CH37310). 2001."},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0360","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40658-023-00586-z","article-title":"Quantitative (177)Lu SPECT\/CT imaging for personalized dosimetry using a ring-shaped CZT-based camera","volume":"10","author":"Danieli","year":"2023","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.zemedi.2026.03.011_b0365","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/630813","article-title":"Reduction of collimator correction artefacts with bayesian reconstruction in spect","volume":"2011","author":"Kangasmaa","year":"2011","journal-title":"Int J Mol Imaging"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0370","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40658-021-00362-x","article-title":"Theranostic SPECT reconstruction for improved resolution: application to radionuclide therapy dosimetry","volume":"8","author":"Marquis","year":"2021","journal-title":"EJNMMI Phys"},{"issue":"supplement 1","key":"10.1016\/j.zemedi.2026.03.011_b0375","article-title":"Complete Monte Carlo based SPECT reconstruction using PyTomography and SIMIND","volume":"66","author":"Polson","year":"2025","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40658-017-0201-8","article-title":"Fast GPU-based Monte Carlo code for SPECT\/CT reconstructions generates improved 177Lu images","volume":"5","author":"Ryd\u00e9n","year":"2018","journal-title":"EJNMMI Phys"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0385","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2967\/jnumed.115.159012","article-title":"No. 26: joint EANM\/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy","volume":"57","author":"Ljungberg","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.zemedi.2026.03.011_b0390","unstructured":"EARL, 177Lu SPECT\/CT Accreditation pilot study. 2022 24.11.2025]; Available from: https:\/\/earl.eanm.org\/177lu-spect-ct\/."},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0395","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40658-021-00397-0","article-title":"A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT\/CT imaging performed within the MRTDosimetry project","volume":"8","author":"Tran-Gia","year":"2021","journal-title":"EJNMMI Phys"},{"issue":"21","key":"10.1016\/j.zemedi.2026.03.011_b0400","doi-asserted-by":"crossref","first-page":"R119","DOI":"10.1088\/0031-9155\/57\/21\/R119","article-title":"A review of partial volume correction techniques for emission tomography and their applications in neurology, cardiology and oncology","volume":"57","author":"Erlandsson","year":"2012","journal-title":"Phys Med Biol"},{"issue":"12","key":"10.1016\/j.zemedi.2026.03.011_b0405","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/acd982","article-title":"Activity recovery for differently shaped objects in quantitative SPECT","volume":"68","author":"Minguez Gabina","year":"2023","journal-title":"Phys Med Biol"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0410","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40658-022-00446-2","article-title":"The magnitude of the partial volume effect in SPECT imaging of the kidneys: a phantom study","volume":"9","author":"Grings","year":"2022","journal-title":"EJNMMI Phys"},{"issue":"3","key":"10.1016\/j.zemedi.2026.03.011_b0415","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2967\/jnumed.124.268520","article-title":"No. 32: a MIRD recovery coefficient model for resolution characterization and shape-specific partial-volume correction","volume":"66","author":"Marquis","year":"2025","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0420","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40658-024-00697-1","article-title":"Partial volume correction for Lu-177-PSMA SPECT","volume":"11","author":"Liu","year":"2024","journal-title":"EJNMMI Phys"},{"issue":"6","key":"10.1016\/j.zemedi.2026.03.011_b0425","doi-asserted-by":"crossref","first-page":"980","DOI":"10.2967\/jnumed.123.266889","article-title":"A deep-learning-based partial-volume correction method for quantitative (177)Lu SPECT\/CT imaging","volume":"65","author":"Leube","year":"2024","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.zemedi.2026.03.011_b0430","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00259-021-05538-2","article-title":"[(68)Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [(177)Lu]Lu-PSMA-617 treatment","volume":"49","author":"Peters","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"14","key":"10.1016\/j.zemedi.2026.03.011_b0435","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1088\/0031-9155\/61\/14\/5107","article-title":"The influence of triple energy window scatter correction on activity quantification for 1\u20097\u20097Lu molecular radiotherapy","volume":"61","author":"Robinson","year":"2016","journal-title":"Phys Med Biol"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0440","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13550-016-0172-0","article-title":"Quantitative accuracy of (177)Lu SPECT reconstruction using different compensation methods: phantom and patient studies","volume":"6","author":"Hippel\u00e4inen","year":"2016","journal-title":"EJNMMI Res"},{"issue":"18","key":"10.1016\/j.zemedi.2026.03.011_b0445","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ac093b","article-title":"Motion estimation and correction in SPECT, PET and CT","volume":"66","author":"Kyme","year":"2021","journal-title":"Phys Med Biol"},{"issue":"10","key":"10.1016\/j.zemedi.2026.03.011_b0450","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/mp.12483","article-title":"Impact of respiratory motion and acquisition settings on SPECT liver dosimetry for radioembolization","volume":"44","author":"Bastiaannet","year":"2017","journal-title":"Med Phys"},{"key":"10.1016\/j.zemedi.2026.03.011_b0455","unstructured":"Maximilian P, Reymann M, Brandon C. Jones, PhD, Francesc Massanes, PhD, and A. Hans Vija, PhD, Data-driven mitigation of SPECT motion-induced artifacts. 2025, Siemens Healthineers: Clinical White Papers, Siemens Healthineers."},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0460","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40658-020-00303-0","article-title":"Impact of dead time on quantitative (177)Lu-SPECT (QSPECT) and kidney dosimetry during PRRT","volume":"7","author":"Desy","year":"2020","journal-title":"EJNMMI Phys"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0465","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40658-022-00484-w","article-title":"Impact of the dead-time correction method on quantitative (177)Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapy","volume":"9","author":"Desy","year":"2022","journal-title":"EJNMMI Phys"},{"issue":"4","key":"10.1016\/j.zemedi.2026.03.011_b0470","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2967\/jnumed.120.245548","article-title":"Deep-learning generation of synthetic intermediate projections improves (177)Lu SPECT images reconstructed with sparsely acquired projections","volume":"62","author":"Ryden","year":"2021","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.zemedi.2026.03.011_b0475","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1053\/j.semnuclmed.2024.06.003","article-title":"Future perspectives of artificial intelligence in bone marrow dosimetry and individualized radioligand therapy","volume":"54","author":"Moraitis","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"6","key":"10.1016\/j.zemedi.2026.03.011_b0480","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Sjogreen Gleisner","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0485","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13550-023-00952-z","article-title":"Optimization of the radiation dosimetry protocol in Lutetium-177-PSMA therapy: toward clinical implementation","volume":"13","author":"Peters","year":"2023","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.zemedi.2026.03.011_b0490","unstructured":"Ivashchenko O, Noordzij W. Scan speed reduction in post-therapy [177Lu]LuPSMA SPECT\/CT. in EANM Annual Congress 2024. 2024."},{"key":"10.1016\/j.zemedi.2026.03.011_b0495","first-page":"P909","article-title":"Deep learning denoising of (177)Lu-PSMA triple-bed SPECT using clinical (68)Ga PET\/CT images as digital phantoms","volume":"64","author":"Westerbergh","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.zemedi.2026.03.011_b0500","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2967\/jnumed.124.268910","article-title":"Assessment of [177Lu]Lu-DOTATATE dosimetry from high-speed whole-body recordings provided by a 360\u00b0 cadmium\u2013zinc\u2013telluride camera compared with results from a conventional anger-camera protocol","volume":"66","author":"Zaragori","year":"2025","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0505","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40658-024-00627-1","article-title":"Comparison of a 3D CZT and conventional SPECT\/CT system for quantitative Lu-177 SPECT imaging","volume":"11","author":"Nuttens","year":"2024","journal-title":"EJNMMI Phys"},{"issue":"20","key":"10.1016\/j.zemedi.2026.03.011_b0510","doi-asserted-by":"crossref","first-page":"9721","DOI":"10.7150\/thno.63860","article-title":"Practical considerations for quantitative clinical SPECT\/CT imaging of alpha particle emitting radioisotopes","volume":"11","author":"Benabdallah","year":"2021","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.zemedi.2026.03.011_b0515","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/ijnm.IJNM_58_20","volume":"35","author":"Kamaleshwaran","year":"2020","journal-title":"Indian J Nucl Med"},{"issue":"11","key":"10.1016\/j.zemedi.2026.03.011_b0520","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1007\/s00259-020-04725-x","article-title":"Post-therapy imaging of (225)Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor","volume":"47","author":"Ocak","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.zemedi.2026.03.011_b0525","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s00259-020-05024-1","article-title":"Image-based dosimetry for (225)Ac-PSMA-I&T therapy using quantitative SPECT","volume":"48","author":"Gosewisch","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.zemedi.2026.03.011_b0530","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1007\/s00259-022-06092-1","article-title":"Biodistribution and dosimetry for combined [(177)Lu]Lu-PSMA-I&T\/[(225)Ac]Ac-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging","volume":"50","author":"Delker","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.zemedi.2026.03.011_b0535","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1007\/s00259-024-06681-2","article-title":"Image-based dosimetry for [(225)Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics","volume":"51","author":"Liubchenko","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0540","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40658-024-00635-1","article-title":"Quantitative SPECT\/CT imaging of actinium-225 for targeted alpha therapy of glioblastomas","volume":"11","author":"Tulik","year":"2024","journal-title":"EJNMMI Phys"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0545","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40658-022-00481-z","article-title":"Quantitative SPECT\/CT imaging of lead-212: a phantom study","volume":"9","author":"Kvassheim","year":"2022","journal-title":"EJNMMI Phys"},{"issue":"4","key":"10.1016\/j.zemedi.2026.03.011_b0550","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2967\/jnumed.123.267189","article-title":"First-in-human (212)Pb-PSMA-targeted alpha-therapy SPECT\/CT imaging in a patient with metastatic castration-resistant prostate cancer","volume":"65","author":"Griffiths","year":"2024","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0555","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40658-025-00763-2","article-title":"Gamma camera imaging characteristics of (203\/212)Pb as a theragnostic pair for targeted alpha therapy: a feasibility study","volume":"12","author":"Kastner","year":"2025","journal-title":"EJNMMI Phys"},{"issue":"3","key":"10.1016\/j.zemedi.2026.03.011_b0560","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ijrobp.2015.07.005","article-title":"Absorbed doses and risk estimates of (211)At-MX35 F(ab')2 in intraperitoneal therapy of ovarian cancer patients","volume":"93","author":"Cederkrantz","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.zemedi.2026.03.011_b0565","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1109\/42.712122","article-title":"Application of reconstruction-based scatter compensation to thallium-201 SPECT: implementations for reduced reconstructed image noise","volume":"17","author":"Kadrmas","year":"1998","journal-title":"IEEE Trans Med Imaging"},{"issue":"7","key":"10.1016\/j.zemedi.2026.03.011_b0570","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2967\/jnumed.119.233411","article-title":"Radiation dosimetry in 177Lu-PSMA-617 therapy using a single posttreatment SPECT\/CT scan: a novel methodology to generate time-and tissue-specific dose factors","volume":"61","author":"Jackson","year":"2020","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0575","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.117.193706","article-title":"Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a single measurement after 4 days","volume":"59","author":"H\u00e4nscheid","year":"2018","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.zemedi.2026.03.011_b0580","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2967\/jnumed.122.264594","article-title":"Toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy","volume":"64","author":"Brosch-Lenz","year":"2023","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.zemedi.2026.03.011_b0585","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.2967\/jnumed.120.256255","article-title":"A novel time-activity information-sharing approach using nonlinear mixed models for patient-specific dosimetry with reduced imaging time points: application in SPECT\/CT after (177)Lu-DOTATATE","volume":"62","author":"Devasia","year":"2021","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.zemedi.2026.03.011_b0590","doi-asserted-by":"crossref","first-page":"566","DOI":"10.2967\/jnumed.123.266268","article-title":"Single-time-point renal dosimetry using nonlinear mixed-effects modeling and population-based model selection in [(177)Lu]Lu-PSMA-617 therapy","volume":"65","author":"Hardiansyah","year":"2024","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0595","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40658-021-00409-z","article-title":"Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT\/CT study","volume":"8","author":"Chicheportiche","year":"2021","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.zemedi.2026.03.011_b0600","article-title":"Current prospects and future directions of single time point dosimetry in radiopharmaceutical therapy: a systematic review","author":"Sadeghi","year":"2025","journal-title":"Nucl Med Mol Imag"},{"issue":"9","key":"10.1016\/j.zemedi.2026.03.011_b0605","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2967\/jnumed.122.265338","article-title":"Single-time-point imaging for dosimetry after [(177)Lu]Lu-DOTATATE: accuracy of existing methods and novel data-driven models for reducing sensitivity to time-point selection","volume":"64","author":"Wang","year":"2023","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1016\/j.zemedi.2026.03.011_b0610","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.2967\/jnumed.123.266871","article-title":"Impact of the reference multiple-time-point dosimetry protocol on the validity of single-time-point dosimetry for [(177)Lu]Lu-PSMA-I&T therapy","volume":"65","author":"Resch","year":"2024","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.zemedi.2026.03.011_b0615","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/RLU.0000000000004599","article-title":"177Lu-DOTATATE theranostics: predicting renal dosimetry from pretherapy 68Ga-DOTATATE PET and clinical biomarkers","volume":"48","author":"Peterson","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"12","key":"10.1016\/j.zemedi.2026.03.011_b0620","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1007\/s00259-022-05883-w","article-title":"Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with (177)Lu-PSMA I&T therapy","volume":"49","author":"Xue","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.zemedi.2026.03.011_b0625","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1007\/s00259-024-06737-3","article-title":"Pre-therapy PET-based voxel-wise dosimetry prediction by characterizing intra-organ heterogeneity in PSMA-directed radiopharmaceutical theranostics","volume":"51","author":"Xue","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.zemedi.2026.03.011_b0630","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11523-025-01151-7","article-title":"PSMA PET imaging in the management of patients with metastatic castration-resistant prostate cancer treated with radioligand therapy","volume":"20","author":"Kuo","year":"2025","journal-title":"Target Oncol"},{"issue":"6","key":"10.1016\/j.zemedi.2026.03.011_b0635","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1007\/s00259-021-05661-0","article-title":"89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man","volume":"49","author":"Priv\u00e9","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"12","key":"10.1016\/j.zemedi.2026.03.011_b0640","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.2967\/jnumed.116.176206","article-title":"First-in-human imaging with 89Zr-Df-IAB2M anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake","volume":"57","author":"Pandit-Taskar","year":"2016","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0645","first-page":"134","article-title":"Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy","volume":"48","author":"Konijnenberg","year":"2007","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0650","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.semradonc.2020.07.002","article-title":"The radiobiology of radiopharmaceuticals","volume":"31","author":"Morris","year":"2021","journal-title":"Semin Radiat Oncol"},{"issue":"9","key":"10.1016\/j.zemedi.2026.03.011_b0655","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ac5fe0","article-title":"Dosimetry in targeted alpha therapy. A systematic review: current findings and what is needed","volume":"67","author":"Tronchin","year":"2022","journal-title":"Phys Med Biol"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0660","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.semradonc.2020.07.008","article-title":"Dosimetry for optimized, personalized radiopharmaceutical therapy","volume":"31","author":"Graves","year":"2021","journal-title":"Semin Radiat Oncol"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0665","doi-asserted-by":"crossref","first-page":"19938","DOI":"10.1038\/s41598-024-70417-3","article-title":"3D small-scale dosimetry and tumor control of (225)Ac radiopharmaceuticals for prostate cancer","volume":"14","author":"Peter","year":"2024","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.zemedi.2026.03.011_b0670","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2967\/jnumed.125.269470","article-title":"Establishing in vitro dosimetric models and dose-effect relationships for (177)Lu-DOTATATE in neuroendocrine tumors","volume":"66","author":"Tamborino","year":"2025","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0675","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40658-020-0276-5","article-title":"Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity","volume":"7","author":"Tamborino","year":"2020","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.zemedi.2026.03.011_b0680","first-page":"12","article-title":"Introduction to radiobiology of targeted radionuclide therapy","volume":"2","author":"Pouget","year":"2015","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"10.1016\/j.zemedi.2026.03.011_b0685","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00259-022-05821-w","article-title":"In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T","volume":"49","author":"Ruigrok","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.zemedi.2026.03.011_b0690","doi-asserted-by":"crossref","unstructured":"Sgouros, G., et al., MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med, 2010. 51(2): p. 311-28.","DOI":"10.2967\/jnumed.108.058651"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0695","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40658-023-00567-2","article-title":"Estimation of relative biological effectiveness of (225)Ac compared to (177)Lu during [(225)Ac]Ac-PSMA and [(177)Lu]Lu-PSMA radiopharmaceutical therapy using TOPAS\/TOPAS-nBio\/MEDRAS","volume":"10","author":"Rumiantcev","year":"2023","journal-title":"EJNMMI Phys"},{"issue":"23","key":"10.1016\/j.zemedi.2026.03.011_b0700","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/abbc81","article-title":"Microdosimetry-based determination of tumour control probability curves for treatments with (225)Ac-PSMA of metastatic castration resistant prostate cancer","volume":"65","author":"M\u00ednguez Gabi\u00f1a","year":"2020","journal-title":"Phys Med Biol"},{"issue":"6","key":"10.1016\/j.zemedi.2026.03.011_b0705","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Sj\u00f6green Gleisner","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.zemedi.2026.03.011_b0710","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","article-title":"EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry","volume":"37","author":"Hindorf","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"10.1016\/j.zemedi.2026.03.011_b0715","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.7150\/thno.113354","article-title":"Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells","volume":"15","author":"Nguyen","year":"2025","journal-title":"Theranostics"},{"issue":"Suppl 1","key":"10.1016\/j.zemedi.2026.03.011_b0720","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1530\/eje.0.143s009","article-title":"Somatostatin receptors in the haematopoietic system","volume":"143","author":"Oomen","year":"2000","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.zemedi.2026.03.011_b0725","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1088\/0031-9155\/56\/8\/001","article-title":"An image-based skeletal dosimetry model for the ICRP reference adult male\u2013internal electron sources","volume":"56","author":"Hough","year":"2011","journal-title":"Phys Med Biol"},{"issue":"2","key":"10.1016\/j.zemedi.2026.03.011_b0730","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11547-020-01239-2","article-title":"Bone marrow magnetic resonance imaging: physiologic and pathologic findings that radiologist should know","volume":"126","author":"Chiarilli","year":"2021","journal-title":"Radiol Med"},{"issue":"4","key":"10.1016\/j.zemedi.2026.03.011_b0735","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.zemedi.2022.01.005","article-title":"Quantification of the volume fraction of fat, water and bone mineral in spongiosa for red marrow dosimetry in molecular radiotherapy by using a dual-energy (SPECT\/)CT","volume":"32","author":"Salas-Ramirez","year":"2022","journal-title":"Z Med Phys"},{"issue":"20","key":"10.1016\/j.zemedi.2026.03.011_b0740","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/ab4476","article-title":"Quantification of the trabecular bone volume fraction for bone marrow dosimetry in molecular radiotherapy by using a dual-energy (SPECT\/)CT","volume":"64","author":"Salas-Ramirez","year":"2019","journal-title":"Phys Med Biol"},{"issue":"2","key":"10.1016\/j.zemedi.2026.03.011_b0745","doi-asserted-by":"crossref","DOI":"10.1088\/1361-6560\/aa9a28","article-title":"Quantification of fat fraction in lumbar vertebrae: correlation with age and implications for bone marrow dosimetry in molecular radiotherapy","volume":"63","author":"Salas-Ramirez","year":"2018","journal-title":"Phys Med Biol"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0750","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40658-025-00816-6","article-title":"Comparison of imaging-based bone marrow dosimetry methodologies and their dose-effect relationships in [(177)Lu]Lu-PSMA-617 RLT including a novel method with active marrow localization","volume":"13","author":"Peterson","year":"2025","journal-title":"EJNMMI Phys"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0755","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40658-024-00636-0","article-title":"Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT\/CT","volume":"11","author":"Grob","year":"2024","journal-title":"EJNMMI Phys"},{"issue":"9","key":"10.1016\/j.zemedi.2026.03.011_b0760","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.2967\/jnumed.123.265484","article-title":"Specific uptake in the bone marrow causes high absorbed red marrow doses during [(177)Lu]Lu-DOTATATE treatment","volume":"64","author":"Hemmingsson","year":"2023","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1016\/j.zemedi.2026.03.011_b0765","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.zemedi.2026.03.011_b0770","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.zemedi.2026.03.011_b0775","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of (177)Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","author":"Garske-Roman","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.zemedi.2026.03.011_b0780","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","article-title":"Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based (177)Lu-DOTATATE treatment of NET patients","volume":"49","author":"Sundlov","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.zemedi.2026.03.011_b0785","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial","volume":"46","author":"Del Prete","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1016\/j.zemedi.2026.03.011_b0790","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162303","article-title":"Investigating the effect of ligand amount and injected therapeutic activity: a simulation study for 177Lu-labeled PSMA-targeting peptides","volume":"11","author":"Kletting","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.zemedi.2026.03.011_b0795","doi-asserted-by":"crossref","first-page":"20041","DOI":"10.1038\/s41598-019-56603-8","article-title":"The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: a simulation study using a PBPK model","volume":"9","author":"Begum","year":"2019","journal-title":"Sci Rep"}],"container-title":["Zeitschrift f\u00fcr Medizinische Physik"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939388926000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939388926000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:34:48Z","timestamp":1789223688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939388926000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":159,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0939388926000231"],"URL":"https:\/\/doi.org\/10.1016\/j.zemedi.2026.03.011","relation":{},"ISSN":["0939-3889"],"issn-type":[{"value":"0939-3889","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State-of-the-art and future developments in dosimetry for SSTR- and PSMA-targeting radioligand therapies","name":"articletitle","label":"Article Title"},{"value":"Zeitschrift f\u00fcr Medizinische Physik","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.zemedi.2026.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier GmbH on behalf of DGMP, \u00d6GMP and SSRMP.","name":"copyright","label":"Copyright"}]}}